PRESTIGE BIOPHARMA 프레스티지바이오파마 Prestigebiopharma

Company
Global R&D
Pipeline
- Biosimilar
  - Overview
  - HD201
  - HD204
  - PBP1502
- Innovative Drug
  - Overview
  - PBP1510
  - PBP1710
  - IDC001
  - mAbs
  - bs-Abs
  - Fusion-Abs
- Vaccines
- Diagnostics
- PAUF
Investors
Newsroom
- News
- Media
- PR Materials
Careers
Contact
한국어

Select Page

Disclosure

Contact

Biosimilars

Overview
HD201
HD204
PBP1502

First-in-Class Antibody

Overview
PBP1510
PBP1710
IDC001
mAbs
bs-Abs
Fusion-Abs

Vaccines

Diagnosics

PAUF

Global R&D

Global Campus
Research Center, Singapore
IDC R&D

Investors

Careers

Company

About us
History
Our Purpose
Our Responsibility

Newsroon

News
Media
PR Materials

Contact

Pipeline

Biosimilars

Overview

HD201

HD204

PBP1502

First-in-Class Antibody

Overview

PBP1510

PBP1710

IDC001

mAbs

bs-Abs

fusion-Abs

Vaccines

Diagnostics

PAUF

Global R&D

Global Campus

Research Center, Singapore

IDC R&D

Investors

Careers

Company

About Us

History

Our Purpose

Our Responsibiltiy

Newsroom

News

Media

PR Materials

Copyright © 2023 Prestige Biopharma Ltd. All Rights Reserved.

Connect with us on LinkedIn ｜ Data Policy

Prestige Biopharma Group Sites

o

o

한국어 (Korean)